Edition:
United States

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

47.35USD
20 Jul 2018
Change (% chg)

$-0.63 (-1.31%)
Prev Close
$47.98
Open
$48.24
Day's High
$48.24
Day's Low
$47.22
Volume
7,526
Avg. Vol
42,156
52-wk High
$68.91
52-wk Low
$17.07

Latest Key Developments (Source: Significant Developments)

Urogen Pharma Submits Investigational New Drug Application For UGN-102 For The Treatment Of LG NMIBC
Wednesday, 11 Jul 2018 08:00am EDT 

July 11 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR UGN-102 (VESIGEL™) FOR THE TREATMENT OF LOW-GRADE NON-MUSCLE INVASIVE BLADDER CANCER (LG NMIBC).UROGEN PHARMA LTD - IF ACCEPTED, COMPANY EXPECTS TO BEGIN A PHASE 2B CLINICAL TRIAL IN UNITED STATES IN Q3 2018.  Full Article

Urogen Pharma Reports Q4 Loss Per Share Of $0.74
Thursday, 15 Mar 2018 07:00am EDT 

March 15 (Reuters) - Urogen Pharma Ltd ::UROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.74.Q4 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S.‍TOP-LINE DATA FROM OLYMPUS PIVOTAL TRIAL ARE EXPECTED IN Q3 2018.​.‍POTENTIAL APPROVAL AND COMMERCIAL LAUNCH OF MITOGEL IN UNITED STATES IS TARGETED FOR H2 2019​.‍AS OF DECEMBER 31, 2017, CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TOTALED $73.0 MILLION​.‍ ASSUMING POSITIVE RESULTS, PLANNED SUBMISSION OF NDA TO U.S. FDA IN Q1 2019 FOR MITOGEL​.  Full Article

Urogen Announces Proposed Public Offering Of Ordinary Shares
Tuesday, 16 Jan 2018 04:04pm EST 

Jan 16 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES.UROGEN PHARMA SAYS IT HAS FILED WITH U.S. SEC IN CONNECTION WITH A PUBLIC OFFERING OF 1.1 MILLION ORDINARY SHARES.  Full Article

Urogen Pharma Q3 loss per share $0.02
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Urogen Pharma Ltd :Urogen Pharma reports third quarter 2017 financial results and recent corporate developments.Q3 loss per share $0.02.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.  Full Article

Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma ‍​
Wednesday, 8 Nov 2017 09:02am EST 

Nov 8 (Reuters) - UroGen Pharma Ltd -:Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing ‍​.  Full Article

Urogen Pharma receives FDA fast track designation for Mitogel
Tuesday, 29 Aug 2017 08:30am EDT 

Aug 29 (Reuters) - Urogen Pharma Ltd :Urogen Pharma receives FDA fast track designation for Mitogel for the treatment of upper tract urothelial carcinoma (UTUC).Mitogel currently being evaluated in ongoing pivotal phase 3 olympus clinical trial in patients with low-grade UTUC.  Full Article

UroGen Pharma Q2 loss per share $0.70
Monday, 14 Aug 2017 04:05pm EDT 

Aug 14 (Reuters) - Urogen Pharma Ltd :UroGen Pharma reports second quarter 2017 financial results and recent corporate developments.Q2 loss per share $0.70.Q2 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Jay Moorin reports a 11.5 pct passive stake in Urogen Pharma
Thursday, 20 Jul 2017 04:55pm EDT 

July 20 (Reuters) - Urogen Pharma Ltd :Jay Moorin reports a 11.5 percent passive stake in Urogen Pharma Ltd as of May 9, 2017 - SEC filing.  Full Article

Allergan submits investigational NDA for rtgel in combination with botox
Wednesday, 19 Jul 2017 08:30am EDT 

July 19 (Reuters) - Urogen Pharma Ltd ::Investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to FDA by Allergan.Says it will receive a milestone payment of $7.5 million under its exclusive worldwide licensing agreement with allergan.Urogen Pharma - milestone payment resulting from Allergan's submission of investigational new drug application for rtgel in combination with botox to U.S. FDA.  Full Article

Arkin Communications reports 13.32 pct stake in Urogen Pharma Ltd as on May 4, 2017
Tuesday, 30 May 2017 08:58am EDT 

May 30 (Reuters) - Arkin Communications Ltd: :Arkin Communications Ltd reports a 13.32 percent stake in Urogen Pharma Ltd as on May 4, 2017 - sec filing.  Full Article

Photo

Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.